KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment.

Grace Lai-Hung Wong, Edward Gane, Calvin Q Pan, Scott Fung, Mang M Ma, Namiki Izumi, Shalimar, Seng Gee Lim, Wan-Long Chuang, Rajiv Mehta, Young-Suk Lim, Leland J Yee, John F Flaherty, Frida Abramov, Hongyuan Wang, Maria Buti

Aliment Pharmacol Ther 63(1) 132-144

PMID40793974
PMCIDPMC12690228
DOI10.1111/apt.70327
发表日期2025-08-12
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 multi panel km;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other。
摘要

摘要

BACKGROUND: Tenofovir alafenamide (TAF) has shown non-inferior efficacy to tenofovir disoproxil fumarate (TDF), with superior bone and renal safety. AIM: To characterise 5-year TAF efficacy and safety in patients of East Asian ethnicity from pivotal Phase 3 studies. METHODS: Patients were randomised (2:1) to receive TAF or TDF for up to 3 years of double-blind treatment, followed by open-label TAF. Patients either continued TAF or switched from TDF to TAF at Week 96 (TDF → TAF 3 years) or Week 144 (TDF → TAF 2 years) of treatment. Efficacy endpoints (virologic, biochemical and serologic) and safety were assessed. RESULTS: Among 591 patients of East Asian ethnicity (TAF, n = 401; TDF → TAF 3 years, n = 84; TDF → TAF 2 years, n = 106), high rates of virologic control were achieved (89%, 94% and 92%, respectively) at Year 5 (missing = failure analysis). At Year 5, rates of alanine aminotransferase normalisation (85%, 90% and 78%) and hepatitis B e antigen loss (36%, 43% and 44%) were similar. Following the switch from TDF to TAF, changes in fasting lipid parameters were consistent with removal of the known lipid-lowering effect of TDF. However, changes in the total cholesterol to high-density lipoprotein ratio (marker of cardiovascular risk) were minimal and comparable in all groups by Year 5. Renal and bone parameters improved after switching. CONCLUSIONS: Through 5 years, rates of virologic suppression were high in East Asian patients treated with TAF or switched from TDF to TAF. TAF and TDF were well tolerated, with improved renal and bone safety observed in patients switching from TDF to TAF.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Viral suppression and ALT normalisation. (A) Proportion of patients with HBV DNA < 29 IU/mL by study visit over 5 years. (B) Proportion of patients with ALT >ULN at baseline achieving ALT normalisation by study visit over 5 years using AASLD 2018 [3] (men ≤ 35 U/L and women ≤ 25 U/L) criteria. Missing = failure analysis. AASLD, American Association for the Study of Liver Diseases; ALT, alanine amino transferase; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.
非 KM Figure
FIGURE 2FIGURE 2 Changes in fasting lipids and body weight. Median changes in (A) fasting total cholesterol, (B) fasting HDL cholesterol, (C) fasting LDL cholesterol, (D) fasting triglycerides, (E) fasting total cholesterol/HDL cholesterol ratio and (F) body weight by study week over 5 years. HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.
非 KM Figure
FIGURE 3FIGURE 3 Changes in BMD. Mean percentage change in hip (A) and (B) spine BMD from baseline by study visit over 5 years of treatment. BMD, bone mineral density; SD, standard deviation; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.
非 KM Figure
FIGURE 4FIGURE 4 Changes in eGFR CG and β 2 M/Cr. Median change from baseline in eGFR CG (A) and serum β 2 M/Cr (B) by study visit over 5 years. eGFR CG , estimated glomerular filtration rate by Cockcroft‐Gault; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; β 2 M/Cr, urine β2‐microglobulin‐to‐creatinine.
非 KM Figure